Biofrontera Statistics
Share Statistics
Biofrontera has 7.75M shares outstanding. The number of shares has increased by 52.26% in one year.
| Shares Outstanding | 7.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 39.79% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.21M |
| Failed to Deliver (FTD) Shares | 71.80K |
| FTD / Avg. Volume | 2.25% |
Short Selling Information
The latest short interest is 457.12K, so 5.9% of the outstanding shares have been sold short.
| Short Interest | 457.12K |
| Short % of Shares Out | 5.9% |
| Short % of Float | 7.37% |
| Short Ratio (days to cover) | 0.08 |
Valuation Ratios
The PE ratio is -0.21 and the forward PE ratio is -1.1.
| PE Ratio | -0.21 |
| Forward PE | -1.1 |
| PS Ratio | 0.13 |
| Forward PS | 0.1 |
| PB Ratio | 0.89 |
| P/FCF Ratio | -0.17 |
| PEG Ratio | n/a |
Enterprise Valuation
Biofrontera Inc. has an Enterprise Value (EV) of 8.34M.
| EV / Earnings | -0.41 |
| EV / Sales | 0.24 |
| EV / EBITDA | -0.45 |
| EV / EBIT | -0.37 |
| EV / FCF | -0.33 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.28 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.81 |
| Total Debt / Capitalization | 44.89 |
| Cash Flow / Debt | -6.38 |
| Interest Coverage | -37.8 |
Financial Efficiency
Return on equity (ROE) is -4.2% and return on capital (ROIC) is -222.65%.
| Return on Equity (ROE) | -4.2% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | -222.65% |
| Revenue Per Employee | 410.49K |
| Profits Per Employee | -242.54K |
| Employee Count | 83 |
| Asset Turnover | 1.22 |
| Inventory Turnover | 1.6 |
Taxes
| Income Tax | 14.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.77% in the last 52 weeks. The beta is 0.51, so Biofrontera 's price volatility has been higher than the market average.
| Beta | 0.51 |
| 52-Week Price Change | -48.77% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 48.84 |
| Average Volume (20 Days) | 3.19M |
Income Statement
In the last 12 months, Biofrontera had revenue of 34.07M and earned -20.13M in profits. Earnings per share was -13.02.
| Revenue | 34.07M |
| Gross Profit | 16.63M |
| Operating Income | -22.68M |
| Net Income | -20.13M |
| EBITDA | -18.45M |
| EBIT | -22.68M |
| Earnings Per Share (EPS) | -13.02 |
Balance Sheet
The company has 1.34M in cash and 5.40M in debt, giving a net cash position of -4.06M.
| Cash & Cash Equivalents | 1.34M |
| Total Debt | 5.40M |
| Net Cash | -4.06M |
| Retained Earnings | -99.65M |
| Total Assets | 18.52M |
| Working Capital | 5.90M |
Cash Flow
In the last 12 months, operating cash flow was -24.89M and capital expenditures -5.00K, giving a free cash flow of -24.90M.
| Operating Cash Flow | -24.89M |
| Capital Expenditures | -5.00K |
| Free Cash Flow | -24.90M |
| FCF Per Share | -16.1 |
Margins
Gross margin is 48.8%, with operating and profit margins of -66.56% and -59.09%.
| Gross Margin | 48.8% |
| Operating Margin | -66.56% |
| Pretax Margin | -59.04% |
| Profit Margin | -59.09% |
| EBITDA Margin | -54.16% |
| EBIT Margin | -66.56% |
| FCF Margin | -73.08% |
Dividends & Yields
BFRI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1251.92% |
| FCF Yield | -307.49% |
Analyst Forecast
The average price target for BFRI is $7, which is 573.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 573.1% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 5, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -7.95 |
| Piotroski F-Score | 2 |